Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Long-term benefits of nusinersen in later-onset spinal muscular atrophy

This article has been updated

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Change history

  • 17 May 2019

    In the original version of this article, the abbreviation CMAP was misspelt as CAMP. The spelling has been corrected in the HTML and PDF versions of the article.


Original article

  1. Darras, B. T. et al. Nusinersin in later-onset spinal muscular atrophy. Long-term results from the phase ½ studies. Neurology (2019)

    Article  PubMed  PubMed Central  Google Scholar 

Further reading

  1. Groen, E. J. et al. Advances in therapy for spinal muscular atrophy: promises and challenges. Nat. Rev. Neurol. 14, 214–224 (2018)

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Ian Fyfe.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fyfe, I. Long-term benefits of nusinersen in later-onset spinal muscular atrophy. Nat Rev Neurol 15, 368–369 (2019).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing